Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 ---- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) ---- Fast Track designation (FTD) granted to bempikibart for the treatment of alopecia areata (AA); SIGNAL-AA Part A results presented as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting ---- Cash and cash equivalents of $65.5 million as of March 31, 2025 expected to provide financial runway into ...